Dean Hart, Michelle L. Shuffett, Curtis Rhine, Justin Molignoni
Company Description
RS BioTherapeutics is developing a groundbreaking drug platform to address inflammatory lung diseases like Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF). Their science-backed approach offers new treatment avenues not just for these respiratory diseases, but many others that could be addressed using their innovative platform.